Prognostic factors for survival in cervical cancer patients with bone metastasis

Purpose: To investigate the prognostic factors for survival in uterine cervical cancer patients who developed bone metastasis. Materials and Methods: Cervical cancer patients with bone metastasis who were treated at the present institute from April 1996 to September 2010 were identified from the authors’ institutional tumor registries. Primary disease, follow-up, and recurrence data were collected and retrospectively reviewed. Univariate and multivariate analyses of prognostic factors for survival were performed. Results: A total of 37 patients that developed cervical cancer bone metastasis were included in the authors’ database. The median survival time after recurrence was 12 months. Univariate analysis revealed that patients with a disease-free interval (DFI) of ten months or less achieved significantly shorter survival after bone metastasis detection than those with a DFI of 11 months or more (median: 8.5 months versus 17 months, p < 0.0001). Multivariate analysis also showed that DFI of ten months or less was a significant predictor of short survival (p = 0.0018). Conclusions: The DFI was found to be independent prognostic factors for survival in cervical cancer patients who developed bone metastasis.

Bone metastasis; Cervical cancer; Prognostic factors; Survival.

[1] American Cancer Society: Cancer Facts and Figures 2011. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-029771.pdf.

[2] Ajiki W., Tsukuma H., Oshima A.: “Research Group for Populationbased Cancer Registration in Japan. Cancer incidence and incidence rates in Japan in 1999: estimates based on data from 11 populationbased cancer registries”. Jpn. J. Clin. Oncol., 2004, 34, 352.

[3] Höckel M., Dornhöfer N.: “Pelvic exenteration for gynaecological tumours: achievements and unanswered questions”. Lancet Oncol., 2006, 7, 837.

[4] Landoni F., Maneo A., Colombo A., Placa F., Milani R., Perego P., Favini G., Ferri L., Mangioni C.: “Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer”. Lancet, 1997, 350, 535.

[5] Benedet J.L., Odicino F., Maisonneuve P., Beller U., Creasman W.T., Heintz A.P., Ngan H.Y., Pecorelli S.: “Carcinoma of the cervix uteri”. Int. J. Gynaecol. Obstet., 2003, 83, 41.

[6] Long H.J.: “Management of metastatic cervical cancer: review of the literature”. J. Clin. Oncol., 2007, 25, 2966.

[7] Thanapprapasr D., Nartthanarung A., Likittanasombut P., Na Ayudhya N.I., Charakorn C., Udomsubpayakul U. et al.: “Subhadarbandhu T., Wilailak S. Bone metastasis in cervical cancer patients over a 10-year period”. Int. J. Gynecol. Cancer, 2010, 20, 373.

[8] Abdul-Karim F.W., Kida M., Wentz W.B., Carter J.R., Sorensen K., Macfee M., Zika J., Makley J.T.: “Bone metastasis from gynecologic carcinomas: a clinicopathologic study”. Gynecol. Oncol., 1990, 39, 108.

[9] Matsuyama T., Tsukamoto N., Imachi M., Nakano H.: “Bone metastasis from cervix cancer”. Gynecol. Oncol., 1989, 32, 72.

[10] Omura G.A., Blessing J.A., Vaccarello L., Berman M.L., Clarke- Pearson D.L., Mutch D.G., Anderson B.: “Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study”. J. Clin. Oncol., 1997, 15, 165.

[11] Vermorken J.B., Zanetta G., De Oliveira C.F., van der Burg M.E., Lacave A.J., Teodorovic I., Boes G.H., Colombo N.: “Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma of the uterine cervix: an EORTC Gynecological Cancer Cooperative Group study”. Ann. Oncol., 2001, 12, 967.

[12] Mabuchi S., Isohashi F., Yoshioka Y., Temma K., Takeda T., Yamamoto T., Enomoto T., Morishige K., Inoue T., Kimura T.: “Prognostic factors for survival in patients with recurrent cervical cancer previously treated with radiotherapy”. Int. J. Gynecol. Cancer, 2010, 20, 834.

[13] Fagundes H., Perez C.A., Grigsby P.W., Lockett M.A.: “Distant metastases after irradiation alone in carcinoma of the uterine cervix”. Int. J. Radiat. Oncol. Biol. Phys., 1992, 24, 197.

[14] Barmeir E., Langer O., Levy J.I., Nissenbaum M., DeMoor N.G., Blumenthal N.J.: “Unusual skeletal metastases in carcinoma of the cervix”. Gynecol. Oncol., 1985, 20, 307.

[15] Ratanatharathorn V., Powers W.E., Steverson N., Han I., Ahmad K., Grimm J.: “Bone metastasis from cervical cancer”. Cancer, 1994, 73, 2372.

[16] Disibio G., French S.W.: “Metastatic patterns of cancers: results from a large autopsy study”. Arch. Pathol. Lab. Med., 2008, 132, 931.

[17] Tiwari A., Aggarwal T., Lal P.: “Carcinoma of uterine cervix with isolated metastasis to fibula and its unusual behavior: report of a case and review of literature”. J. Cancer Res. Ther., 2006, 2, 79.

[18] Blythe J.G., Cohen M.H., Buchsbaum H.J., Latourette H.B.: “Bony metastases from carcinoma of cervix. Occurrence, diagnosis, and treatment”. Cancer, 1975, 36, 475.

[19] Kanayama T., Mabuchi S., Kimura T.: “Calcaneal metastasis in uterine cervical cancer: A case report and a review of the literature”. Eur. J. Gynecol. Oncol., 2011, in press.

[20] Liu F.Y., Yen T.C., Chen M.Y., Lai C.H., Chang T.C., Chou H.H. et al.: “Detection of hematogenous bone metastasis in cervical cancer: 18F-fluorodeoxyglucose-positron emission tomography versus computed tomography and magnetic resonance imaging”. Cancer, 2009, 115, 5470.

[21] Mabuchi S., Morimoto A., Fujita M., Isohashi K., Kimura T.: “GCSF induces focal intense bone marrow FDG uptake mimicking multiple bone metastases from uterine cervical cancer: a case report and review of the literature”. Eur. J. Gynecol. Oncol., 2011, in press.

[22] Catalano L., Del Vecchio S., Petruzziello F., Fonti R., Salvatore B., Martorelli C., Califano C., Caparrotti G., Segreto S., Pace L., Rotoli B.: “Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosis”. Ann. Hematol., 2007, 86, 415.